

INVESTOR GUIDE

QBIOTICS GROUP

Pre IPO

Approximately 40% of pharmaceutical products are derived from natural sources, including plants, according to the World Health Organization.

Aspirin and chemotherapy drugs like paclitaxel highlight how nature has long served as a powerful engine for drug discovery – an approach that underpins QBiotech's biodiscovery platform.

QBiotech was established in 2010 as a pharmaceutical development spin-out of EcoBiotech, before merging in 2017 to form the QBiotech Group.

EcoBiotech was founded in 2000 by former CSIRO research scientists Dr Paul Reddell and Dr Victoria Gordon.

Reddell, QBiotech's chief scientific officer, built an international reputation in tropical forest ecology and management, while Gordon served as managing director and CEO for more than two decades before transitioning to an executive director role in 2023.

The company develops cell-signalling small-molecule therapeutics, currently targeting oncology and wound healing – markets with high unmet medical need.

Its proprietary EcoLogic discovery platform identifies plant-derived small molecules with specific biological activity, generating first-in-class assets with lower development risk than conventional discovery models.

Interim CEO and managing director Ebru Davidson said the approach had produced a validated commercial product and clinical pipeline.

"We discovered our oncology compound tigilanol tiglate (EBC 46) from the seed of *Fontainea picosperma*, commonly known as the blushwood tree, found in north Queensland rainforests," she said.

The seeds contain bioactive chemicals that act as natural indicators of biological activity.

Tigilanol tiglate is approved as a veterinary formulation for treating canine non-metastatic mast cell tumours under the trade name STELFONTA in key jurisdictions, including the US, UK, Europe and Australia.

"Having a veterinary-approved drug was a



deliberate de-risking model by the company, showing the potential of our EcoLogic platform and that we can take a molecule from nature all the way to registration," Davidson said.

The compound is in human phase II clinical trials for soft-tissue sarcoma and head and neck cancers.

In soft-tissue sarcoma, tigilanol tiglate has received US Food & Drug Administration (FDA) Orphan Drug Designation.

Data from the first stage of a phase IIa soft-tissue sarcoma study showed an 80% response rate in injected tumours.

The data also suggest tigilanol tiglate may deliver durable responses and activate the tumour immune microenvironment in challenging 'cold' tumours.

The second stage of the trial is currently recruiting patients at the Memorial Sloan Kettering Cancer Center in New York.

Final data from the head and neck cancer phase II trial is forecast later this year.

"There is huge potential for this drug beyond soft-tissue sarcoma and head and neck cancers," Davidson said.

QBiotech's second asset, EBC-1013, a wound-healing drug, is currently recruiting for a phase I trial in patients with venous leg ulcers.

Davidson said QBiotech continues to progress toward an ASX listing, hitting key milestones, and assessing market conditions to position the company for success.



EBRU DAVIDSON
INTERIM CEO &
MANAGING DIRECTOR

■ **QBiotech Group**

■ Pre IPO

■ **Key areas:** Biotechnology – clinical stage oncology and wound healing

■ **Key personnel:** Ebru Davidson, Interim CEO & MD; Simon Pollard, Interim Chairman; Dr Victoria Gordon, Executive Director, Chief Strategy Officer & Co-Founder; Dr Paul Reddell, Executive Director, Chief Scientific Officer & Co-Founder

■ **Website:** qbiotics.com



SCAN THIS QR CODE
TO LEARN MORE

